Smart and Hearty Bundle

Buy VIVA and EVOLV together now and save £50

Exclusive online offer, with limited time only. Buy the body composition monitor 'VIVA' and the blood pressure monitor 'EVOLV' together now for only £178.99 from £228.99 (recommended retail price). Plus free delivery.

This offer is valid between 2 - 30 September 2019, cannot be combined with other promotions and applies to online orders via www.omron-healthcare.co.uk only.

VIVA
£99.00
  • Gives a more complete picture of your body’s condition
  • Clinically Validated results
  • Integrates with "OMRON connect" app
EVOLV
20% off
Alexa compatible
£129.99
  • All-in-one design
  • Connected
  • Intelli Wrap Cuff (22-42cm)

VIVA & EVOLV

Help you understand your cardiovascular health

VIVA

Body Composition Monitor

Always ready. Just step on. VIVA is a body composition monitor with clinically validated accuracy of key parameters that allow you to better understand your heart's health (visceral fat, fat and skeletal muscle) and are proven to be predictive for cardiovascular events.1

EVOLV

Blood Pressure Monitor

No tubes. No wires. Simply accurate. EVOLV is an easy to use, all-in-one upper arm blood pressure monitor. You can take accurate readings in any position around the upper arm2 with the Intelli Wrap Cuff and track progress via smartphone.

Why Better Together?

Monitoring your body composition together with blood pressure and heart rate can help you understand your cardiovascular health and can help take action in time.

Smart Ecosystem

Track your health data in one place

VIVA and EVOLV are Bluetooth-enabled devices. They can transfer your readings to your smartphone. With the ‘OMRON connect’ app, you can track your progress, share the results with your doctor, and get a deeper understanding of your health over time.

OMRON connect is compatible with Android and iOS operating systems. View supported devices.


1 J.P. Despre´s. Body Fat Distribution and Risk of Cardiovascular Disease. Circulation September 4, 2012, Volume 126, Issue 10
2 Bilo G et al. Hypertens Res 2017. 40(6): 573-580